Stem Cell-Based Cardiac Tissue Engineering

Article

Abstract

Cardiovascular diseases are the leading cause of death worldwide, and cell-based therapies represent a potential cure for patients with cardiac diseases such as myocardial infarction, heart failure, and congenital heart diseases. Towards this goal, cardiac tissue engineering is now being investigated as an approach to support cell-based therapies and enhance their efficacy. This review focuses on the latest research in cardiac tissue engineering based on the use of embryonic, induced pluripotent, or adult stem cells. We describe different strategies such as direct injection of cells and/or biomaterials as well as direct replacement therapies with tissue mimics. In this regard, the latest research has shown promising results demonstrating the improvement of cardiac function with different strategies. It is clear from recent studies that the most important consideration to be addressed by new therapeutic strategies is long-term functional improvement. For this goal to be realized, novel and efficient methods of cell delivery are required that enable high cell retention, followed by electrical integration and mechanical coupling of the injected cells or the engineered tissue to the host myocardium.

Keywords

Cardiac tissue engineering Stem cells Cell therapy Regenerative medicine Induced pluripotent stem cells Embryonic stem cells 

References

  1. 1.
    Boilson, B. A., et al. (2010). Device therapy and cardiac transplantation for end-stage heart failure. Current Problems in Cardiology, 35(1), 8–64.PubMedCrossRefGoogle Scholar
  2. 2.
    Kirkpatrick, J. N., Wiegers, S. E., & Lang, R. M. (2010). Left ventricular assist devices and other devices for end-stage heart failure: utility of echocardiography. Current Cardiology Reports, 12(3), 257–264.PubMedCrossRefGoogle Scholar
  3. 3.
    Nelson, T. J., Behfar, A., & Terzic, A. (2008). Strategies for therapeutic repair: The “R3” regenerative medicine paradigm. Clinical and Translational Science, 1(2), 168–171.PubMedCrossRefGoogle Scholar
  4. 4.
    Murry, C. E., Reinecke, H., & Pabon, L. M. (2006). Regeneration gaps: Observations on stem cells and cardiac repair. Journal of the American College of Cardiology, 47(9), 1777–1785.PubMedCrossRefGoogle Scholar
  5. 5.
    Rossini, R., et al. (2010). Prevention of left ventricular remodelling after acute myocardial infarction: An update. Recent Patents on Cardiovascular Drug Discovery, 5(3), 196–207.PubMedCrossRefGoogle Scholar
  6. 6.
    Radisic, M., et al. (2008). Cardiac tissue engineering using perfusion bioreactor systems. Nature Protocols, 3(4), 719–738.PubMedCrossRefGoogle Scholar
  7. 7.
    Reinecke, H., et al. (1999). Survival, integration, and differentiation of cardiomyocyte grafts: A study in normal and injured rat hearts. Circulation, 100(2), 193–202.PubMedGoogle Scholar
  8. 8.
    Herrmann, J. L., et al. (2009). Cell-based therapy for ischemic heart disease: A clinical update. The Annals of Thoracic Surgery, 88(5), 1714–1722.PubMedCrossRefGoogle Scholar
  9. 9.
    Yoon, S. J., et al. (2009). Regeneration of ischemic heart using hyaluronic acid-based injectable hydrogel. Journal of Biomedical Materials Research. Part B, Applied Biomaterials, 91(1), 163–171.PubMedCrossRefGoogle Scholar
  10. 10.
    Singelyn, J. M., & Christman, K. L. (2010). Injectable materials for the treatment of myocardial infarction and heart failure: The promise of decellularized matrices. Journal of Cardiovascular Translational Research, 3(5), 478–486.PubMedCrossRefGoogle Scholar
  11. 11.
    Christoforou, N., et al. (2010). Implantation of mouse embryonic stem cell-derived cardiac progenitor cells preserves function of infarcted murine hearts. PloS One, 5(7), e11536.PubMedCrossRefGoogle Scholar
  12. 12.
    Adler, E. D., et al. (2010). The cardiomyocyte lineage is critical for optimization of stem cell therapy in a mouse model of myocardial infarction. The FASEB Journal, 24(4), 1073–1081.PubMedCrossRefGoogle Scholar
  13. 13.
    Caspi, O., et al. (2007). Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. Journal of the American College of Cardiology, 50(19), 1884–1893.PubMedCrossRefGoogle Scholar
  14. 14.
    Fernandes, S., et al. (2010). Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats. Journal of Molecular and Cellular Cardiology, 49(6), 941–949.PubMedCrossRefGoogle Scholar
  15. 15.
    Laflamme, M. A., et al. (2007). Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nature Biotechnology, 25(9), 1015–1024.PubMedCrossRefGoogle Scholar
  16. 16.
    van Laake, L. W., et al. (2009). Improvement of mouse cardiac function by hESC-derived cardiomyocytes correlates with vascularity but not graft size. Stem Cell Research, 3(2–3), 106–112.PubMedCrossRefGoogle Scholar
  17. 17.
    Nelson, T. J., et al. (2009). Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation, 120(5), 408–416.PubMedCrossRefGoogle Scholar
  18. 18.
    Lu, W. N., et al. (2009). Functional improvement of infarcted heart by co-injection of embryonic stem cells with temperature-responsive chitosan hydrogel. Tissue Engineering. Part A, 15(6), 1437–1447.PubMedCrossRefGoogle Scholar
  19. 19.
    Fujimoto, K. L., et al. (2009). Naive rat amnion-derived cell transplantation improved left ventricular function and reduced myocardial scar of postinfarcted heart. Cell Transplantation, 18(4), 477–486.PubMedCrossRefGoogle Scholar
  20. 20.
    Smits, A. M., et al. (2009). Human cardiomyocyte progenitor cell transplantation preserves long-term function of the infarcted mouse myocardium. Cardiovascular Research, 83(3), 527–535.PubMedCrossRefGoogle Scholar
  21. 21.
    Landa, N., et al. (2008). Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation, 117(11), 1388–1396.PubMedCrossRefGoogle Scholar
  22. 22.
    Wall, S. T., et al. (2010). Biomimetic matrices for myocardial stabilization and stem cell transplantation. Journal of Biomedical Materials Research. Part A, 95(4), 1055–1066.PubMedCrossRefGoogle Scholar
  23. 23.
    Dengler, J., et al. (2010). Engineered heart tissue enables study of residual undifferentiated embryonic stem cell activity in a cardiac environment. Biotechnol Bioeng, 108, 704–719.PubMedCrossRefGoogle Scholar
  24. 24.
    Hansen, A., et al. (2010). Development of a drug screening platform based on engineered heart tissue. Circulation Research, 107(1), 35–44.PubMedCrossRefGoogle Scholar
  25. 25.
    Passier, R., van Laake, L. W., & Mummery, C. L. (2008). Stem-cell-based therapy and lessons from the heart. Nature, 453(7193), 322–329.PubMedCrossRefGoogle Scholar
  26. 26.
    Segers, V. F. M., & Lee, R. T. (2008). Stem-cell therapy for cardiac disease. Nature, 451(7181), 937–942.PubMedCrossRefGoogle Scholar
  27. 27.
    Gnecchi, M., et al. (2005). Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nature Medicine, 11(4), 367–368.PubMedCrossRefGoogle Scholar
  28. 28.
    Jawad, H., et al. (2007). Myocardial tissue engineering: A review. Journal of Tissue Engineering and Regenerative Medicine, 1(5), 327–342.PubMedCrossRefGoogle Scholar
  29. 29.
    De Falco, M., Cobellis, G., & De Luca, A. (2009). Proliferation of cardiomyocytes: A question unresolved. Frontiers in Bioscience (Elite Ed), 1, 528–536.Google Scholar
  30. 30.
    Thomson, J. A., et al. (1998). Embryonic stem cell lines derived from human blastocysts. Science, 282(5391), 1145–1147.PubMedCrossRefGoogle Scholar
  31. 31.
    Stevens, K. R., et al. (2009). Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proceedings of the National Academy of Sciences of the United States of America, 106(39), 16568–16573.PubMedCrossRefGoogle Scholar
  32. 32.
    Stevens, K. R., et al. (2009). Scaffold-free human cardiac tissue patch created from embryonic stem cells. Tissue Engineering. Part A, 15(6), 1211–1222.PubMedCrossRefGoogle Scholar
  33. 33.
    Kreutziger, K. L., & Murry, C. E. (2011). Engineered human cardiac tissue. Pediatr Cardiol, 32, 334–341.PubMedCrossRefGoogle Scholar
  34. 34.
    Ke, Q., et al. (2005). Embryonic stem cells cultured in biodegradable scaffold repair infarcted myocardium in mice. Sheng Li Xue Bao, 57(6), 673–681.PubMedGoogle Scholar
  35. 35.
    Nussbaum, J., et al. (2007). Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. The FASEB Journal, 21(7), 1345–1357.PubMedCrossRefGoogle Scholar
  36. 36.
    Chen, Q. Z., et al. (2010). An elastomeric patch derived from poly(glycerol sebacate) for delivery of embryonic stem cells to the heart. Biomaterials, 31(14), 3885–3893.PubMedCrossRefGoogle Scholar
  37. 37.
    Engelmayr, G. C., Jr., et al. (2008). Accordion-like honeycombs for tissue engineering of cardiac anisotropy. Nature Materials, 7(12), 1003–1010.PubMedCrossRefGoogle Scholar
  38. 38.
    Guo, X. M., et al. (2006). Creation of engineered cardiac tissue in vitro from mouse embryonic stem cells. Circulation, 113(18), 2229–2237.PubMedCrossRefGoogle Scholar
  39. 39.
    Gwak, S. J., et al. (2008). The effect of cyclic strain on embryonic stem cell-derived cardiomyocytes. Biomaterials, 29(7), 844–856.PubMedCrossRefGoogle Scholar
  40. 40.
    Boyd, N. L., et al. (2011). Microvascular mural cell functionality of human embryonic stem cell-derived mesenchymal cells. Tissue Eng Part A, 15, 1897–1907.CrossRefGoogle Scholar
  41. 41.
    Ferreira, L. S., et al. (2007). Vascular progenitor cells isolated from human embryonic stem cells give rise to endothelial and smooth muscle like cells and form vascular networks in vivo. Circulation Research, 101(3), 286–294.PubMedCrossRefGoogle Scholar
  42. 42.
    Levenberg, S., et al. (2002). Endothelial cells derived from human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 99(7), 4391–4396.PubMedCrossRefGoogle Scholar
  43. 43.
    Kraehenbuehl, T. P., et al. (2010). Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction. Biomaterials, 32(4), 1102–1109.PubMedCrossRefGoogle Scholar
  44. 44.
    Caspi, O., et al. (2007). Tissue engineering of vascularized cardiac muscle from human embryonic stem cells. Circulation Research, 100(2), 263–272.PubMedCrossRefGoogle Scholar
  45. 45.
    Lesman, A., et al. (2010). Transplantation of a tissue-engineered human vascularized cardiac muscle. Tissue Engineering. Part A, 16(1), 115–125.PubMedCrossRefGoogle Scholar
  46. 46.
    Zhang, J., et al. (2009). Functional cardiomyocytes derived from human induced pluripotent stem cells. Circulation Research, 104(4), e30–e41.PubMedCrossRefGoogle Scholar
  47. 47.
    Deb, A., et al. (2003). Bone marrow-derived cardiomyocytes are present in adult human heart: A study of gender-mismatched bone marrow transplantation patients. Circulation, 107(9), 1247–1249.PubMedCrossRefGoogle Scholar
  48. 48.
    Jackson, K. A., et al. (2001). Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. The Journal of Clinical Investigation, 107(11), 1395–1402.PubMedCrossRefGoogle Scholar
  49. 49.
    Orlic, D., et al. (2003). Bone marrow stem cells regenerate infarcted myocardium. Pediatric Transplantation, 7(Suppl 3), 86–88.PubMedCrossRefGoogle Scholar
  50. 50.
    Orlic, D., et al. (2001). Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proceedings of the National Academy of Sciences of the United States of America, 98(18), 10344–10349.PubMedCrossRefGoogle Scholar
  51. 51.
    Rosenzweig, A. (2006). Cardiac cell therapy—mixed results from mixed cells. The New England Journal of Medicine, 355(12), 1274–1277.PubMedCrossRefGoogle Scholar
  52. 52.
    Oh, H., et al. (2003). Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proceedings of the National Academy of Sciences of the United States of America, 100(21), 12313–12318.PubMedCrossRefGoogle Scholar
  53. 53.
    Beltrami, A. P., et al. (2003). Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell, 114(6), 763–776.PubMedCrossRefGoogle Scholar
  54. 54.
    Laugwitz, K. L., et al. (2005). Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature, 433(7026), 647–653.PubMedCrossRefGoogle Scholar
  55. 55.
    Domian, I. J., et al. (2009). Generation of functional ventricular heart muscle from mouse ventricular progenitor cells. Science, 326(5951), 426–429.PubMedCrossRefGoogle Scholar
  56. 56.
    Johnston, P. V., et al. (2009). Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation, 120(12), 1075–1083. 7 p following 1083.PubMedCrossRefGoogle Scholar
  57. 57.
    Messina, E., et al. (2004). Isolation and expansion of adult cardiac stem cells from human and murine heart. Circulation Research, 95(9), 911–921.PubMedCrossRefGoogle Scholar
  58. 58.
    Chimenti, I., et al. (2010). Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circulation Research, 106(5), 971–980.PubMedCrossRefGoogle Scholar
  59. 59.
    Cheng, K., et al. (2010). Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction. Circulation Research, 106(10), 1570–1581.PubMedCrossRefGoogle Scholar
  60. 60.
    Alper, J. (2009). Geron gets green light for human trial of ES cell-derived product. Nat Biotech, 27(3), 213–214.CrossRefGoogle Scholar
  61. 61.
    Chen, S. L., et al. (2004). Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. The American Journal of Cardiology, 94(1), 92–95.PubMedCrossRefGoogle Scholar
  62. 62.
    Herreros, J., et al. (2003). Autologous intramyocardial injection of cultured skeletal muscle-derived stem cells in patients with non-acute myocardial infarction. European Heart Journal, 24(22), 2012–2020.PubMedCrossRefGoogle Scholar
  63. 63.
    Menasche, P., et al. (2003). Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. Journal of the American College of Cardiology, 41(7), 1078–1083.PubMedCrossRefGoogle Scholar
  64. 64.
    Murry, C. E., Field, L. J., & Menasche, P. (2005). Cell-based cardiac repair: Reflections at the 10-year point. Circulation, 112(20), 3174–3183.PubMedCrossRefGoogle Scholar
  65. 65.
    Pagani, F. D., et al. (2003). Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. Journal of the American College of Cardiology, 41(5), 879–888.PubMedCrossRefGoogle Scholar
  66. 66.
    Siminiak, T., et al. (2004). Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: Phase I clinical study with 12 months of follow-up. American Heart Journal, 148(3), 531–537.PubMedCrossRefGoogle Scholar
  67. 67.
    Sung, N. S., et al. (2003). Central challenges facing the national clinical research enterprise. JAMA, 289(10), 1278–1287.PubMedCrossRefGoogle Scholar
  68. 68.
    Wollert, K. C., et al. (2004). Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet, 364(9429), 141–148.PubMedCrossRefGoogle Scholar
  69. 69.
    Hotta, A., & Ellis, J. (2008). Retroviral vector silencing during iPS cell induction: An epigenetic beacon that signals distinct pluripotent states. Journal of Cellular Biochemistry, 105(4), 940–948.PubMedCrossRefGoogle Scholar
  70. 70.
    Maherali, N., et al. (2007). Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell, 1(1), 55–70.PubMedCrossRefGoogle Scholar
  71. 71.
    Woltjen, K., et al. (2009). Piggybac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature, 27, 559–567.Google Scholar
  72. 72.
    Laflamme, M. A., & Murry, C. E. (2005). Regenerating the heart. Nature Biotechnology, 23(7), 845–856.PubMedCrossRefGoogle Scholar
  73. 73.
    Dengler, J., & Radisic, M. (2007). Tissue engineering approaches for the development of a contractile cardiac patch. Future Cardiology, 3(4), 425–434.PubMedCrossRefGoogle Scholar
  74. 74.
    Shimizu, T., et al. (2009). Cell sheet-based myocardial tissue engineering: New hope for damaged heart rescue. Current Pharmaceutical Design, 15(24), 2807–2814.PubMedCrossRefGoogle Scholar
  75. 75.
    Zimmermann, W. H., et al. (2006). Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nature Medicine, 12(4), 452–458.PubMedCrossRefGoogle Scholar
  76. 76.
    Song, H., et al. (2010). Interrogating functional integration between injected pluripotent stem cell-derived cells and surrogate cardiac tissue. Proceedings of the National Academy of Sciences of the United States of America, 107(8), 3329–3334.PubMedCrossRefGoogle Scholar
  77. 77.
    Song, H., Zandstra, P. W., and Radisic, M. (2011). Engineered Heart Tissue Model of Diabetic Myocardium. Tissue Eng Part A.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Institute of Biomaterials and Biomedical EngineeringUniversity of TorontoTorontoCanada
  2. 2.Toronto General Research InstituteUniversity Health Network, MaRS CentreTorontoCanada
  3. 3.Department of Chemical Engineering and Applied ChemistryUniversity of TorontoTorontoCanada
  4. 4.Heart and Stroke/Richard Lewar Centre of ExcellenceUniversity of TorontoTorontoCanada

Personalised recommendations